Tafamidis Cuts Cardiovascular Death and Hospitalization Risk for Up to 90 Months
A post hoc analysis of the ATTR-ACT trial and its long-term extension found continuous tafamidis treatment significantly reduced cardiovascular death ...
Tag: Cardiovascular-Related
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development